Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Distinct pattern of peripheral lymphocyte subsets in Graves' disease with persistency of anti-TSHR autoantibodies.
|
31366254 |
2020 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Maternal or neonatal thyroid-stimulating hormone (TSH) receptor antibodies in children of mothers with Graves' disease, and TSH at 3-7 days of age are good predictors of which neonates will have problems.
|
31789723 |
2020 |
Graves Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The serum levels of TRAb were strongly correlated with the circulating concentrations of both FT3 (ρ = 0.667; p < 0.0001) and FT4 (ρ = 0.628; p < 0.001) in iGD patient, but not in the aGD ones (FT3: ρ = 0.231; p = 0.058; FT4: ρ = 0.096; p = 0.435).
|
31407208 |
2020 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thyrotropin receptor antibodies (TRAbs) play a crucial role in the pathogenesis of Graves disease (GD).
|
30517711 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The lack of central tolerance to a large portion of TSHR may explain the relatively high frequency of autoimmunity related to TSHR and its clinical consequence, GD.
|
31379878 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thyrotropin receptor is an autoantigen in GD, and its immunogenicity has been examined.
|
31434818 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The serum thyrotropin receptor antibody (TRAb) titers of Graves' disease (GD) patients are known to increase after radioiodine (RAI) therapy, and they can remain high for years.
|
30426886 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The Thyrotropin receptor antibody (TRAb) is the main driver of Graves' disease (GD) and its most common extra-thyroidal manifestation: thyroid eye disease (TED).
|
30401900 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The TSH receptor (TSHR) is the major autoantigen in Graves' disease (GD).
|
30822352 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Graves' disease (GD) is caused by autoantibodies against the thyrotropin receptor (TRAb), and among the three types of TRAbs, only the stimulating type (TSI) is known to be associated with GD.
|
31453725 |
2019 |
Graves Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Rapid growth and early metastasis of PTC with coexisting Graves' disease in this patient can be related to a combination of multiple factors including preserved TSHR expression, reduced SLC5A5 expression, and TFG/NTRK1 rearrangement.
|
30092570 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings, combined with the clinical conditions-an ophthalmologic evaluation (that showed the presence of exophthalmos without lagophthalmos and visual acuity deficiency), thyroid ultrasound, and TSH receptor antibody positivity-led to a diagnosis of Graves' disease.
|
30626069 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Transgenic NOD.<i>H2<sup>h4</sup></i> mice that express the human (h) TSHR A-subunit in the thyroid gland spontaneously develop pathogenic TSHR autoantibodies resembling those in patients with Graves disease.
|
30944161 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
|
31237525 |
2019 |
Graves Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Whereas elevated thyroid hormone synthesis by the thyroid in Graves' disease can be treated by antithyroid agents, for the pathogenic activation of TSHR in retro-orbital fibroblasts of the eye, leading to Graves' orbitopathy (GO), no causal TSHR directed therapy is available.
|
30351237 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
With the 20 confirmed GD risk-related SNPs, our wGRS-prediction model could predict patients with GD from the general population (AUC 0.70 [95% CI: 0.69 to 0.71]) and did especially well in predicting patients with GD with persisting thyroid-stimulating hormone receptor antibody positive [pTRAb+; AUC 0.74 (95% CI: 0.72 to 0.76)].
|
30649410 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The present study aimed to confirm the existence of TSHR in exosomes secreted from thyroid cells and to define the role of TSHR exosomes in GD.
|
31062662 |
2019 |
Graves Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These cells, known as fibrocytes, express relatively high levels of functional TSH receptor (TSHR) through which they can be activated by TSH and the GD-specific pathogenic antibodies that underpin thyroid overactivity.
|
30215690 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves' disease.
|
31560118 |
2019 |
Graves Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In alemtuzumab-induced TD, the autoantibodies against the thyrotropin receptor (TRAb) play a major role, and 2 main aspects distinguish this condition from the spontaneous form: (1) up to 20% of GD cases exhibit a fluctuating course, with alternating phases of hyper- and hypothyroidism, due to the coexistence of TRAb with stimulating and blocking function; (2) TRAb are also positive in about 70% of hypothyroid patients, with blocking TRAb responsible for nearly half of the cases.
|
31602359 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.
|
31023276 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
TSHR blocking antibodies were present in one (3%) patient with HT and in two (1%) patients with GD; these two GD patients were also bridge assay positive but TSAb bioassay negative.
|
31207654 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have previously reported that EBV-infected B cells with thyrotropin receptor autoantibodies (TRAbs) on their surface [TRAb(+) EBV(+) cells] were present in the peripheral blood mononuclear cells (PBMCs) of healthy adult controls and patients with Graves' disease, and that TRAbs released in the culture medium of PBMCs containing TRAb(+) EBV(+) cells by EBV reactivation.
|
31580214 |
2019 |
Graves Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The novel Graves disease (GD) model was established in BALB/c mice with recombinant adenovirus expressing the full-length human TSHR (Ad-TSHR289) by three times immunizations for nearly three months.
|
31217394 |
2019 |
Graves Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CEP128 was identified as an important risk locus for GD in the genome-wide genetic analysis, and it was located near TSHR without obvious linkage disequilibrium with TSHR.
|
30393005 |
2019 |